HOME | CONTACT

BCI-632 Features

  • Novel mechanism-of-action
  • Remarkable neurogenic potency on neural stem cells
  • Potential for wide CNS application
  • Expected to be equally effective in treating depression and cognitive functioning
 

BCI-632

BrainCells is developing this novel drug broadly in CNS. It benefits from a mechanism of action that has the potential to be first in class in cognition and mood disorders.

Highly Neurogenic Compound Targets Cognition and Depression

BCI-632 is a specific and potent antagonist of the metabotropic glutamate receptors 2 and 3. While the compound has not been previously studied in the clinic, it does have an extensive preclinical package.

In both in vitro neurogenesis analysis and animal behavioral studies, BCI-632 is highly neurogenic and equally effective in studies of antidepression effect and cognitive functioning. This highly neurogenic compound has the potential for wide CNS application including cognition, depression and anxiety.

BrainCells in-licensed BCI-632 in 2007 and has filed and is currently prosecuting both composition of matter and method of use patent protection for the drug.